ReviewJournal of neurogastroenterology and motility2018
Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.
Review in Journal of neurogastroenterology and motility, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06858384 (From Awareness to Action), which is not on this map. Cited by 110 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study
Who cites it
110 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations.Journal of gastroenterology and hepatology · 2026Pooled it
- Pooled it
- Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Propolis and Its Gastroprotective Effects on NSAID-Induced Gastric Ulcer Disease: A Systematic Review.Nutrients · 2021Pooled it
- Efficacy of Teprenone for Prevention of NSAID-Induced Gastrointestinal Injury: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.Pharmacology research & perspectives · 2020Pooled it
- Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.Hepatology international · 2020Pooled it
- Pooled it
- Diagnostic utility of salivary pepsin in laryngopharyngeal reflux: a systematic review and meta-analysis.Brazilian journal of otorhinolaryngologyPooled it
- Effectiveness of a Collaborative Deprescribing Intervention of Proton Pump Inhibitors on Community-Dwelling Older Adults: The C-SENIoR Pragmatic Non-randomised Controlled Trial.Drugs & aging · 2025Trial
- Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.Clinical and translational science · 2023Trial
- An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding.BMC gastroenterology · 2022Trial
- Trial
- Trial
- Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study.Nutrients · 2020Trial
- Article
- Nonvariceal Upper GI Bleeding in Established Users of Proton-Pump Inhibitors: Higher Incidence But Better Outcomes.Clinical and translational gastroenterology · 2026Observational
- Prevalence of Vitamin B12 Deficiency Among Patients With Type 2 Diabetes Mellitus on Long-Term Metformin Therapy.Cureus · 2026Article
- Inconsistency in the Association Between Proton Pump Inhibitor Use and Dementia Risk: An Updated Meta-Analysis.Brain sciences · 2026Review
- Cobblestone-like Gastric Mucosal Changes on Endoscopy in Dogs with a History of Prolonged Proton Pump Inhibitor Therapy.Animals : an open access journal from MDPI · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophageal reflux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.